Menu

New Guidelines Expand BRCA Screening

US Preventive Services Task Force recommends genetic testing for mutations in the cancer-related genes for more—but not all—women.

Aug 21, 2019
Ashley P. Taylor

ABOVE: © ISTOCK.COM, DUSANPETKOVIC

On Tuesday (August 20), the US Preventive Services Task Force, a panel of federally appointed independent experts that makes recommendations about preventive care, published updated guidelines for testing people for mutations in the genes BRCA1 and BRCA2, some variants of which are associated with increased risks of breast, ovarian, and some other cancers. The new guidelines, which appear in JAMA, expand the group of women recommended to undergo BRCA1/2 risk assessments, but do not recommend broad screening for mutations in the two genes, GenomeWeb reports.

Previous guidelines by the US Preventive Services Task Force (USPSTF) already advised physicians to screen women with family members who have BRCA-related cancers and refer them to genetic counselors as needed, the Associated Press notes. The new guidelines also recommend that doctors perform BRCA1/2 risk assessments on women who have previously been treated for breast, ovarian, fallopian tube, and peritoneal cancers, and who are deemed cancer free, and on women whose ancestry puts them at a higher risk of deleterious BRCA1/2 mutations, such as Ashkenazi Jewish women.

“Whether or not the harms of risk assessment, counseling, testing, and interventions outweigh the benefits depends on a woman’s individual risk profile and family history,” USPSTF member and Stanford University professor of medicine Douglas Owens tells Reuters.

The USPSTF recommends that women who meet the updated screening criteria should be evaluated with a risk assessment tool, which will estimate their odds of having a harmful BRCA1/2 mutation. If the assessments indicate a harmful mutation is likely, then genetic counseling and, possibly, genetic testing could follow.

“Sometimes it makes sense for a woman to only get an assessment and undergo counseling, but not genetic testing,” Owens notes.

See “MyHeritage Launches Health-Related Genetic Test, Ignites Debate

If tests reveal that a woman has BRCA1/2 mutations that put her at an increased risk for cancer, then potential interventions include more screening for BRCA-associated mutations, medications, and surgeries (such as those to remove breasts, ovaries, or fallopian tubes) that could reduce that risk.

Ashley P. Taylor is a New York–based freelance reporter. Follow her on Twitter @crenshawseeds and read her work at ashleyptaylor.com.

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs
Protein Biomarker Discovery and Analysis
Protein Biomarker Discovery and Analysis
Download this application note from Olink Proteomics to learn about the potential of proteomics for accelerating pharmaceutical development and how proteomics offers solutions to common problems facing drug development scientists.
Streamline Beer, Wine, and Food Quality Control and Safety Analyses
Streamline Beer, Wine, and Food Quality Control and Safety Analyses
Download this eBook from Molecular Devices to learn how to conduct high-throughput detection of melamine, detect endotoxin presence using microplates, and analyze beer and wine composition!